← boardnext 2026-11-11
PGEN
Precigen, Incdistress 7/10 · high distress / dilution risk$5.14-3%today-13% from 52w high
Lead: Cervical Cancer
Revenue
$23M
Liquidity
$56M
Runway
0.5 yrs
Shares 1y
+20%
Price & events
+6.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.4%
1D
+3.8%
1W
-4.1%
1M
+29.8%
3M
+8.0%
6M
+209.6%
1Y
+211.5%
2Y
-5.0%
5Y
-53.1%
All
Overview
- Market Cap
- $1.83B
- Enterprise Value
- $1.92B
- Volume
- 167.49K
- 52 Week Range
- $1.52 – $5.92
- Total Shares
- 356.51M
- Float Shares
- 189.66M
- Short %
- 22.83%
- % Held by Insiders
- 13.71%
- % Held by Institutions
- 71.22%
- RVOL
- 0.03x
- Beta
- 1.00
Pipeline stages · 1 programs
PRGN-2009 plus Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-11 Estimated 50% readout ~2026-12-26 | Phase 2 | PRGN-2009 plus Pembrolizumabfast track | Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer | — | recruiting |
Catalyst news & presentations · 2
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2024regulatory submissionFiled (NDA/BLA)PRGN-2012 · rolling BLA submission under accelerated approval pathwaySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-28HC Wainwright & Co.Buy
- 2026-05-14CitizensMarket Outperform
- 2026-05-14HC Wainwright & Co.Buy
- 2026-03-26CitizensMarket Outperform
- 2026-03-26HC Wainwright & Co.Buy
- 2025-11-14HC Wainwright & Co.Buy
Competitors — Cervical Cancer
- LLYELI LILLY & Co$1094.4B · D3
- MRKMerck & Co., Inc.$318.8B · D3
- RCUSArcus Biosciences, Inc.$3.8B · D5
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- NTHINEONC TECHNOLOGIES HOLDINGS, INC.$91M · D9
- PDSBPDS Biotechnology Corp$40M · D7
- RDPTFRadiopharm Theranostics Ltd$24M · D3
- MDNAFMedicenna Therapeutics Corp.$17M · D6
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22ETFs Investing in Precigen Inc Stocks - TradingView
- 2026-07-21Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 - BioSpace
- 2026-07-21Precigen (PGEN) to Release Q2 Financial Results and Discuss Business Progress - GuruFocus
- 2026-07-21Precigen (PGEN) to Release Q2 Financial Results and Discuss Business Progress - GuruFocus
- 2026-07-21Precigen sets 4:30 p.m. ET call for Aug. 4 business update - Stock Titan
- 2026-07-21Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 - Sahm
- 2026-07-16ETFs Investing in Precigen Inc Stocks - TradingView
- 2026-07-16Precigen Inc. (PGEN) Slides 2.64% as Stock Tests Key Support Levels - Mutual Fund Flow - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.